These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 2894309)

  • 1. Enzymatic properties of single-chain and two-chain forms of a Lys158----Glu158 mutant of urokinase-type plasminogen activator.
    Lijnen HR; Van Hoef B; Nelles L; Holmes WE; Collen D
    Eur J Biochem; 1988 Feb; 172(1):185-8. PubMed ID: 2894309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural and functional characterization of mutants of recombinant single-chain urokinase-type plasminogen activator obtained by site-specific mutagenesis of Lys158, Ile159 and Ile160.
    Lijnen HR; Nelles L; Van Hoef B; Demarsin E; Collen D
    Eur J Biochem; 1988 Nov; 177(3):575-82. PubMed ID: 2973984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasminogen activation with single-chain urokinase-type plasminogen activator (scu-PA). Studies with active site mutagenized plasminogen (Ser740----Ala) and plasmin-resistant scu-PA (Lys158----Glu).
    Lijnen HR; Van Hoef B; Nelles L; Collen D
    J Biol Chem; 1990 Mar; 265(9):5232-6. PubMed ID: 1969415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The mechanism of plasminogen activation and fibrin dissolution by single chain urokinase-type plasminogen activator in a plasma milieu in vitro.
    Lijnen HR; Van Hoef B; De Cock F; Collen D
    Blood; 1989 May; 73(7):1864-72. PubMed ID: 2713507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of recombinant human single chain urokinase-type plasminogen activator mutants produced by site-specific mutagenesis of lysine 158.
    Nelles L; Lijnen HR; Collen D; Holmes WE
    J Biol Chem; 1987 Apr; 262(12):5682-9. PubMed ID: 3106341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biochemical properties of conjugates of urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin.
    Dewerchin M; Lijnen HR; Van Hoef B; De Cock F; Collen D
    Eur J Biochem; 1989 Oct; 185(1):141-9. PubMed ID: 2530085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of the enhanced intrinsic activity of single-chain urokinase-type plasminogen activator during ongoing fibrinolysis.
    Fleury V; Lijnen HR; Anglés-Cano E
    J Biol Chem; 1993 Sep; 268(25):18554-9. PubMed ID: 8103046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A monoclonal antibody specific for two-chain urokinase-type plasminogen activator. Application to the study of the mechanism of clot lysis with single-chain urokinase-type plasminogen activator in plasma.
    Declerck PJ; Lijnen HR; Verstreken M; Moreau H; Collen D
    Blood; 1990 May; 75(9):1794-800. PubMed ID: 1691934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of the binding of urokinase-type plasminogen activator (u-PA) to plasminogen, to plasminogen-activator inhibitor-1 and to the u-PA receptor.
    Lijnen HR; De Cock F; Collen D
    Eur J Biochem; 1994 Sep; 224(2):567-74. PubMed ID: 7925373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biochemical properties of recombinant single-chain urokinase-type plasminogen activator mutants with deletion of Asn2 through Phe157 and/or substitution of Cys279 with Ala.
    Lijnen HR; Li XK; Nelles L; Hu MH; Collen D
    Eur J Biochem; 1992 Apr; 205(2):701-9. PubMed ID: 1533368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of fibrin-targeting on clot lysis with urokinase-type plasminogen activator.
    Lijnen HR; Dewerchin M; De Cock F; Collen D
    Thromb Res; 1990 Feb; 57(3):333-42. PubMed ID: 2107593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biochemical characterization of single-chain chimeric plasminogen activators consisting of a single-chain Fv fragment of a fibrin-specific antibody and single-chain urokinase.
    Holvoet P; Laroche Y; Lijnen HR; Van Hoef B; Brouwers E; De Cock F; Lauwereys M; Gansemans Y; Collen D
    Eur J Biochem; 1992 Dec; 210(3):945-52. PubMed ID: 1483477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biochemical properties of recombinant mutants of nonglycosylated single chain urokinase-type plasminogen activator.
    Li XK; Lijnen HR; Nelles L; Hu MH; Collen D
    Biochim Biophys Acta; 1992 Sep; 1159(1):37-43. PubMed ID: 1390910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of a chimaeric plasminogen activator obtained by insertion of the second kringle structure of tissue-type plasminogen activator (amino acids 173 through 262) between residues Asp130 and Ser139 of urokinase-type plasminogen activator.
    Lijnen HR; Piérard L; Reff ME; Gheysen D
    Thromb Res; 1988 Dec; 52(5):431-41. PubMed ID: 3146822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of domain deletion and/or duplication mutants of a recombinant chimera of tissue-type plasminogen activator and urokinase-type plasminogen activator (rt-PA/u-PA).
    Nelles L; Lijnen HR; Van Nuffelen A; Demarsin E; Collen D
    Thromb Haemost; 1990 Aug; 64(1):53-60. PubMed ID: 2148847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of a chimeric plasminogen activator consisting of a single-chain Fv fragment derived from a fibrin fragment D-dimer-specific antibody and a truncated single-chain urokinase.
    Holvoet P; Laroche Y; Lijnen HR; Van Cauwenberge R; Demarsin E; Brouwers E; Matthyssens G; Collen D
    J Biol Chem; 1991 Oct; 266(29):19717-24. PubMed ID: 1918077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional properties of a recombinant chimeric protein with combined thrombin inhibitory and plasminogen-activating potential.
    Lijnen HR; Wnendt S; Schneider J; Janocha E; Van Hoef B; Collen D; Steffens GJ
    Eur J Biochem; 1995 Nov; 234(1):350-7. PubMed ID: 8529664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urokinase mutant with better fibrin-specificity.
    Ma Z; Yu R; Hua Z; Zhu D
    Sci China C Life Sci; 1996 Oct; 39(5):523-33. PubMed ID: 9772355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation with plasmin of tow-chain urokinase-type plasminogen activator derived from single-chain urokinase-type plasminogen activator by treatment with thrombin.
    Lijnen HR; Van Hoef B; Collen D
    Eur J Biochem; 1987 Dec; 169(2):359-64. PubMed ID: 2961562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of the intrinsic fibrinolytic properties of pro-urokinase through a study of plasmin-resistant mutant forms produced by site-specific mutagenesis of lysine(158).
    Gurewich V; Pannell R; Broeze RJ; Mao J
    J Clin Invest; 1988 Dec; 82(6):1956-62. PubMed ID: 2974047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.